D
RenovoRx, Inc. RNXT
$0.98 -$0.01-1.01% NASDAQ
Recommendation
Prev Close
$0.99
Volume
31,013
Avg Vol (90D)
127,444
Market Cap
$36.18M
Dividend & Yield
--
52-Week Range
$0.75 - $1.69
P/E (TTM)
--
EPS (TTM)
-$0.385
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
RenovoRx Reports Initial Revenue and Clinical Trial Progress
4/26/2025 - TipRanks Financial Blog
RenovoRx, Inc. (NASDAQ:RNXT) Sees Large Increase in Short Interest
4/18/2025 - Zolmax
Ramtin Agah Purchases 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) Stock
4/18/2025 - MarketBeat
Ramtin Agah Acquires 15,000 Shares of RenovoRx, Inc. (NASDAQ:RNXT) Stock
4/17/2025 - Ticker Report
RenovoRx (RNXT) Boosts Production of RenovoCath to Meet Rising Demand RNXT Stock News
4/16/2025 - GuruFocus
RenovoRx increases production of RenovoCath
4/16/2025 - TipRanks Financial Blog
RenovoRx increases production of RenovoCath
4/16/2025 - The Fly
RenovoRx Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community
4/16/2025 - Business Wire
RenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires $16,000.00 in Stock
4/15/2025 - MarketBeat
Laurence Marton Buys 12,050 Shares of RenovoRx, Inc. (NASDAQ:RNXT) Stock
4/12/2025 - Ticker Report
RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys $21,840.00 in Stock
4/10/2025 - MarketBeat
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
4/4/2025 - GuruFocus
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
4/4/2025 - Business Wire
RenovoRx (NASDAQ:RNXT) Posts Quarterly Earnings Results
4/2/2025 - Ticker Report
RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Update
4/2/2025 - Ticker Report
RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
4/1/2025 - Business Wire
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
3/28/2025 - GuruFocus
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
3/28/2025 - Business Wire
RenovoRx initiated with bullish view at H.C. Wainwright, here's why
3/27/2025 - The Fly
RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
3/26/2025 - Business Wire
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p. ...
3/20/2025 - GuruFocus
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
3/20/2025 - Business Wire
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
3/19/2025 - GuruFocus
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
3/19/2025 - Business Wire
Short Interest in RenovoRx, Inc. (NASDAQ:RNXT) Increases By 60.7%
3/4/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$43.00K
EBITDA (TTM)
--
EBIT (TTM)
-$10.97M
Net Income (TTM)
-$8.81M
Balance Sheet
Total Assets (Q)
$8.12M
Total Debt (Q)
$278.00K
Total Liabilities (Q)
$3.64M
Book Value Per Share (Q)
$0.1863
Cash Flow
Cash from Operations (TTM)
-$9.13M
Cash from Investing (TTM)
-$12.00K
Cash from Financing (TTM)
$15.12M
Net Change in Cash (TTM)
$5.98M
Filings
Filing Date
Tuesday, April 1, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.66
7-Day Total Return
-4.85%
30-Day Total Return
-0.59%
60-Day Total Return
-27.35%
90-Day Total Return
-23.44%
Year to Date Total Return
-27.94%
1-Year Total Return
-21.16%
2-Year Total Return
-64.75%
3-Year Total Return
-44.63%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $0.75
52-week High
Jan 21, 2025 - $1.69
Valuation
Market Cap
$36.18M - Nano Cap
Enterprise Value
$29.31M
Price/Sales (TTM)
582.35
Price/Book (Q)
5.31
Dividends and Shares
Shares Outstanding
25.11M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
renovorx.com
Phone Number
650 284 4433
Address
4546 El Camino Real
Los Altos, CA 94022
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing... more
NASDAQ 04/28/2025 3:52PM Eastern Quotes delayed